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Abstract
Background
Artemisinin-based combination therapy (ACT) is recommended for uncomplicated Plasmo-
dium vivax malaria in areas of emerging chloroquine resistance. We undertook a systematic
review and individual patient data meta-analysis to compare the efficacies of dihydroartemi-
sinin-piperaquine (DP) and artemether-lumefantrine (AL) with or without primaquine (PQ)
on the risk of recurrent P. vivax.
Methods and findings
Clinical efficacy studies of uncomplicated P. vivax treated with DP or AL and published
between January 1, 2000, and January 31, 2018, were identified by conducting a systematic
review registered with the International Prospective Register of Systematic Reviews
(PROSPERO): CRD42016053310. Investigators of eligible studies were invited to contrib-
ute individual patient data that were pooled using standardised methodology. The effect of
mg/kg dose of piperaquine/lumefantrine, ACT administered, and PQ on the rate of P. vivax
recurrence between days 7 and 42 after starting treatment were investigated by Cox regres-
sion analyses according to an a priori analysis plan. Secondary outcomes were the risk of
recurrence assessed on days 28 and 63. Nineteen studies enrolling 2,017 patients were
included in the analysis. The risk of recurrent P. vivax at day 42 was significantly higher in
the 384 patients treated with AL alone (44.0%, 95% confidence interval [CI] 38.7–49.8) com-
pared with the 812 patients treated with DP alone (9.3%, 95% CI 7.1–12.2): adjusted hazard
ratio (AHR) 12.63 (95% CI 6.40–24.92), p < 0.001. The rates of recurrence assessed at
days 42 and 63 were associated inversely with the dose of piperaquine: AHRs (95% CI) for
every 5-mg/kg increase 0.63 (0.48–0.84), p = 0.0013 and 0.83 (0.73–0.94), p = 0.0033,
respectively. The dose of lumefantrine was not significantly associated with the rate of recur-
rence (1.07 for every 5-mg/kg increase, 95% CI 0.99–1.16, p = 0.0869). In a post hoc analy-
sis, in patients with symptomatic recurrence after AL, the mean haemoglobin increased
0.13 g/dL (95% CI 0.01–0.26) for every 5 days that recurrence was delayed, p = 0.0407.
Coadministration of PQ reduced substantially the rate of recurrence assessed at day 42
after AL (AHR = 0.20, 95% CI 0.10–0.41, p < 0.001) and at day 63 after DP (AHR = 0.08,
95% CI 0.01–0.70, p = 0.0233). Results were limited by follow-up of patients to 63 days or
less and nonrandomised treatment groups.
Conclusions
In this study, we observed the risk of P. vivax recurrence at day 42 to be significantly lower
following treatment with DP compared with AL, reflecting the longer period of post-treatment
prophylaxis; this risk was reduced substantially by coadministration with PQ. We found that
delaying P. vivax recurrence was associated with a small but significant improvement in
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haemoglobin. These results highlight the benefits of PQ radical cure and also the provision
of blood-stage antimalarial agents with prolonged post-treatment prophylaxis.
Author summary
Why was this study done?
• The susceptibility of Plasmodium vivax to chloroquine is decreasing in many malaria-
endemic locations.
• Artemisinin-based combination therapies (ACTs) are recommended in areas of emerg-
ing chloroquine resistance; however, the optimal ACT is not clear.
• Knowledge of the comparative advantages and disadvantages of different ACTs will
help guide national policy makers.
What did the researchers do and find?
• Following a systematic review, individual data from 2,017 patients were pooled from 19
studies undertaken between January 1, 2000, and January 31, 2018.
• Cox regression analysis showed that the risk of recurrence at day 42 was 12-fold greater
following treatment with artemether-lumefantrine (AL) alone compared with dihy-
droartemisinin-piperaquine (DP), although by day 63 the risk of recurrence following
DP was also high.
• For every 5-mg/kg increase in the dose of piperaquine, the risk of recurrence at day 42
fell by 37%.
• A delay in the time to symptomatic recurrence was associated with an increase in
haemoglobin.
• Coadministration with primaquine reduced the risk of recurrence at day 42 after AL by
80% and at day 63 after DP by 92%.
What do these findings mean?
• There is a high risk of recurrence following AL or DP unless they are combined with
primaquine.
• Compared with AL, patients treated with DP have a reduced risk of early P. vivax
recurrence.
• Delaying the time to recurrence was associated with greater haematological recovery,
and this has potential to prevent morbidity related to multiple rapid recurrences by pre-
venting a cumulative risk of anaemia.
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Introduction
Declining efficacy of chloroquine against Plasmodium vivax has been reported at varying
degrees across much of the vivax-endemic world [1]. This erosion of efficacy is observed ini-
tially as breakthrough to patency of the first relapse in tropical strains within 28 days [2–4].
Each episode of recurrent patent parasitaemia is associated with a risk of morbidity, a cumula-
tive risk of anaemia, and increased transmission, threatening malaria control and elimination
efforts [5–8].
Potential options to respond to declining chloroquine efficacy include prescribing a higher
dose of chloroquine or ensuring that radical cure is provided—i.e., combining chloroquine
with primaquine (PQ) [9]. Alternatively, some countries have changed their national antima-
larial guidelines to recommend artemisinin-based combination therapy (ACT) for both P. fal-
ciparum and P. vivax malaria [10]. The ACTs adopted differ, with Cambodia and Indonesia
using dihydroartemisinin-piperaquine (DP) and Papua New Guinea, Solomon Islands, and
Vanuatu using artemether-lumefantrine (AL) [11].
Relapses can be prevented by combining blood schizontocidal treatment and PQ, an 8-ami-
noquinoline with activity against the dormant liver stages of P. vivax [2]. In tropical areas,
relapses can occur within weeks of the initial infection, leading to a further episode of haemo-
lysis, prior to complete haematological recovery from the first episode [12,13]. Partner drugs
in ACTs vary significantly in their terminal elimination half-lives, with the more rapidly elimi-
nated lumefantrine providing a shorter period of post-treatment prophylaxis against early
reinfections and relapses compared with the more slowly eliminated piperaquine [6,14,15].
To inform decisions regarding optimal treatment policy in areas of emerging chloroquine-
resistant P. vivax, we conducted a systematic review and individual patient data meta-analysis
to compare the efficacy of AL and DP for treatment of uncomplicated P. vivax malaria, with
and without PQ, on the risk of early P. vivax recurrence.
Methods
Search strategy and selection criteria
MEDLINE, Web of Science, Embase, and Cochrane Data of Systematic Reviews were searched
in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement (S1 Checklist). As previously described [9,16], prospective studies evalu-
ating the efficacy of antimalarials against uncomplicated P. vivax that were published between
January 1, 2000, and January 31, 2018, in any language were identified (S1 Text).
Two independent investigators undertook the review and extracted the data (RJC and
RNP), resolving discrepancy through discussion. Principal investigators of eligible studies
were invited to share individual patient data and any additional data from eligible unpublished
studies. Studies were included if they assessed treatment with DP or AL with or without PQ.
Studies were excluded if adjunctive drugs were given or PQ was dosed weekly. Individual
patient data shared with the WorldWide Antimalarial Resistance Network (WWARN) were
curated and standardised as described in a data management plan [17].
Data included in this analysis were obtained in accordance with ethical approvals from the
location of origin. See S2 Text for a list of specific ethics committees. Data are requested to be
shared anonymised, and additional review from an ethics committee was not required for the
subsequent analysis according to guidelines of the Oxford Central University Research Ethics
Committee.
Comparative efficacy of ACTs for P. vivax malaria
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002928 October 4, 2019 4 / 21
Procedures
Individual patient data were excluded if baseline parasitaemia involved mixed species or blood
schizontocidal treatment was incomplete. Early PQ was defined as commencement of PQ
within the first 3 days of ACT treatment. Drug doses were calculated from the number of tab-
lets a patient was administered if data were available or were based on the study protocol,
assuming complete adherence. ACT partner drugs were considered determinants for recur-
rence rather than artemisinins, which have short half-lives and are considered determinants
for parasite clearance.
Study sites were classified as having short (median time to patent relapse of 47 days or less)
or long P. vivax relapse periodicity based on estimates from the Malaria Atlas Program for geo-
graphical location [12]. PQ dose was defined as a low dose if the total dose was <5.0 mg/kg or
high dose if the total dose was�5.0 mg/kg [18]. A symptomatic recurrence was defined as
recurrent parasitaemia associated with a temperature of�37.5˚C or a history of fever within
the preceding 24 hours.
Underdosing of piperaquine and lumefantrine was defined as a dose less than the minimum
dose recommended by current World Health Organization (WHO) guidelines for P. falcipa-
rum [19]. DP dosing guidelines were updated by WHO in 2015, after enrolment of patients in
all studies included in this analysis was completed. The revised WHO guidelines recommend a
minimum total dose of piperaquine of�60 mg/kg in patients weighing <25 kg and�48 mg/
kg if weighing�25 kg [19–21]. A minimum total dose of lumefantrine of�29 mg/kg is recom-
mended in patients treated with AL [19].
Outcomes
The primary outcome was the risk of P. vivax recurrence between days 7 and 42. The second-
ary outcomes were the risk of P. vivax recurrence between days 7 and 28 and days 7 and 63.
Statistical analysis
Analyses were undertaken according to an a priori statistical analysis plan [22], unless stated
otherwise, using Stata (version 15.0) and R (version 3.4.0). The protocol was registered in the
International Prospective Register of Systematic Reviews (PROSPERO: CRD42016053310)
prior to undertaking the analysis.
To investigate inclusion bias, baseline characteristics of targeted studies not included in the
analysis were compared with the characteristics of the studies included in the analysis. Study
quality and risk of bias were assessed according to criteria for individual patient data meta-
analyses [23].
Kaplan-Meier survival analyses were used to calculate risk of recurrence according to the
treatment administered. Patients were censored at the first day of any of the following for an
outcome prior to day of the end point: recurrent parasitaemia, the last clinic visit, the last visit
prior to a gap of>18 days between parasite microscopy results, the day of outcome, or the day
of PQ treatment (if�28 days after enrolment).
The association between schizontocidal treatment (AL versus DP), coadministration of PQ,
and the mg/kg dose of each drug component (piperaquine and lumefantrine) with the rate of
P. vivax recurrence was estimated using Cox’s proportional hazards regression. Analyses were
adjusted for potential confounders: age, sex, baseline parasitaemia, baseline haemoglobin, and
regional relapse periodicity, with shared frailty applied for study site. Weight was not included,
because of collinearity with age and geographical region, and parasite prevalence was not
included, because of collinearity with relapse periodicity. Age was categorised for analyses of
mg/kg dose as defined previously by age-related dose effects in P. falciparum [21,24].
Comparative efficacy of ACTs for P. vivax malaria
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Proportional hazards assumptions were tested using Schoenfeld residuals. Figures of risk of
recurrence were generated based on the Cox model, which adjusted for confounders and
assumed no study-site effect. In a sensitivity analysis, the coefficient of variation was calculated
for estimates of primary analyses by removal of one study site at a time to investigate study site
heterogeneity. The coefficient of variation should be interpreted in association with the abso-
lute variation of the effect size. A subgroup analysis restricted the analysis to results from stud-
ies directly comparing DP and AL.
Following preplanned statistical analyses, a post hoc analysis was undertaken to investigate
whether a delay in recurrence was associated with a benefit in clinically relevant outcomes.
In patients with a P. vivax recurrence between day 7 and day 63, the delay in recurrence
was correlated with the mean haemoglobin at the day of recurrence using linear regression,
adjusting for confounding factors (age, sex, baseline parasitaemia, baseline haemoglobin, para-
sitaemia at recurrence, regional relapse periodicity, and PQ use), and with random effects for
study site. Analysis was undertaken separately for all recurrences and just symptomatic
recurrences.
Results
Of 180 prospective P. vivax studies published between January 1, 2000, and January 31, 2018,
26 studies (14.4%) with patients treated with DP or AL were eligible for inclusion. Individual
patient data were available from 18 studies enrolling 4,946 patients, of which 3,640 were
infected with P. vivax (67.7% of the 5,377 targeted patients with P. vivax). Additional data
were available for 45 patients enrolled in these published studies, but not formally reported,
and 736 patients from two unpublished studies.
Of 4,421 P. vivax patients with data available from eligible studies, 2,217 (50.1%) were not
treated with DP or AL, and an additional 187 (4.2%) were excluded for other reasons, resulting
in 2,017 patient records included in the analysis (Fig 1 and S1–S4 Tables). Of those patients,
the median age was 18.0 years (interquartile range [IQR] 8.0–30.0), and 272 (13.5%) were aged
<5 years (Table 1). There were 1,593 patients (79.0%) from 15 studies from the Asia-Pacific
region [6,25–38], 341 patients (16.9%) from three studies from Africa [39–41], and 83 patients
(4.1%) from one study from The Americas [42] (Table 1 and S1 Fig). In total, 812 patients
were treated with DP alone [6,25–27,30,34,37,38], 384 with AL alone [6,26,28,31,36,39–41],
613 with DP plus early PQ [25,29,32,33,35], and 208 with AL plus early PQ [28,36,39,41,42].
Only two studies (from Indonesia and Papua New Guinea) compared treatment with DP and
AL directly [6,26]. Patients were followed for 28 days in one study (n = 38, 1.9%) [39], 42–62
days in 10 studies (n = 814, 40.4%) [6,25,26,28,31,32,36–38,40], 63–84 days in three studies
(n = 390, 19.3%) [27,34,42], and 365 days in five studies (n = 775, 38.4%) [29,30,33,35,41]. The
mg/kg doses of lumefantrine and piperaquine were calculated from the number of tablets
given for 1,281 (63.5%) of 2,017 patients, with dosing for the remaining 736 (36.5%) patients
calculated from the study protocol (Table 1).
All patients treated with DP or DP + PQ were enrolled from the Asia-Pacific region, and
those treated with DP + PQ were all from regions with short relapse periodicity. Patients
treated with AL or AL + PQ were enrolled from the Asia-Pacific region, Africa, and The Amer-
icas, although patients from The Americas were all treated with AL + PQ. Compared with
patients treated with DP or AL alone, patients treated with PQ were older and had lower base-
line parasitaemias and a lower risk of anaemia at enrolment (Table 1). Characteristics of
patients from studies that were targeted but not included were similar, although included
patients were younger and had a more even balance of males and females (S5 Table). The risk
of bias relating to included studies is described in S6 Table.
Comparative efficacy of ACTs for P. vivax malaria
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Schizontocidal treatment with DP alone
Among the 812 patients treated with DP alone, the median total dose of dihydroartemisinin
administered was 6.4 mg/kg (IQR 6.0–7.1; range 3.5–10.6), and the median total dose of piper-
aquine administered was 51.4 mg/kg (IQR 48.0–56.5; range 28.2–84.7) (S2 Fig). In total, 181
patients (22.3%) were administered less than the former WHO target dose, and 303 (37.3%)
patients were administered less than the revised WHO target dose (S3 Fig).
Fig 1. Study flowchart. aOne study was excluded entirely because patients treated with AL or DP all had mixed infections [43]. bIncludes 100 patients treated with
DP and two patients treated with AL who received primaquine at day 28 and were censored at this day. AL, artemether-lumefantrine; DP, dihydroartemisinin-
piperaquine.
https://doi.org/10.1371/journal.pmed.1002928.g001
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Following DP alone, 50 of 812 patients had a recurrence between days 7 and 42, the cumu-
lative risk of recurrence being 1.2% (95% confidence interval [CI] 0.6–2.3) at day 28 and 9.3%
(95% CI 7.1–12.2) at day 42. Of the 505 patients from nine studies with follow-up beyond day
42, an additional 105 patients had a recurrence up to day 63, cumulative risk 39.9% (95% CI
33.9–46.7) at day 63. Risks for individual studies are presented in the Supporting information
(S4 Fig). After adjusting for age, sex, baseline parasitaemia, baseline haemoglobin, regional
relapse periodicity, and study-site clustering, an increased piperaquine dose was associated
Table 1. Demographics and baseline characteristics.
Characteristic DP alone DP and early PQ AL alone AL and early PQ Overall
(n = 812) (n = 613) (n = 384) (n = 208) (n = 2,017)
Sex
Female 349 (43.0%) 294 (48.0%) 144 (37.5%) 75 (36.1%) 862 (42.7%)
Male 463 (57.0%) 319 (52.0%) 240 (62.5%) 133 (63.9%) 1,155 (57.3%)
Age (years)
Median (IQR) 16.0 (7–27.0) 21.0 (12.0–32.0) 13.0 (4.9–24.0) 28.0 (18.5–40.6) 18.0 (8.0–30.0)
<5 124 (15.3%) 42 (6.9%) 96 (25.0%) 10 (4.8%) 272 (13.5%)
5 to <15 252 (31.0%) 166 (27.1%) 115 (29.9%) 29 (13.9%) 562 (27.9%)
�15 436 (53.7%) 405 (66.1%) 173 (45.1%) 169 (81.2%) 1,183 (58.7%)
Weight (kg)
Median (IQR) 45.0 (18.0–54.0) 46.0 (30.0–55.0) 32.0 (15.0–55.0) 61.6 (47.0–71.5) 46.0 (20.0–56.0)
5 to <15 126 (15.5%) 40 (6.5%) 93 (24.2%) 10 (4.8%) 269 (13.3%)
15 to <25 155 (19.1%) 85 (13.9%) 69 (18.0%) 20 (9.6%) 329 (16.3%)
25 to <35 48 (5.9%) 60 (9.8%) 36 (9.4%) 8 (3.8%) 152 (7.5%)
35 to <45 76 (9.4%) 82 (13.4%) 19 (4.9%) 6 (2.9%) 183 (9.1%)
45 to <55 208 (25.6%) 182 (29.7%) 66 (17.2%) 31 (14.9%) 487 (24.1%)
55 to <80 193 (23.8%) 156 (25.4%) 99 (25.8%) 100 (48.1%) 548 (27.2%)
�80 6 (0.7%) 8 (1.3%) 2 (0.5%) 33 (15.9%) 49 (2.4%)
Relapse periodicity
Long 265 (32.6%) 0 (0%) 230 (59.9%) 194 (93.3%) 689 (34.2%)
Short 547 (67.4%) 613 (100.0%) 154 (40.1%) 14 (6.7%) 1,328 (65.8%)
Geographical region
Asia-Pacific 812 (100.0%) 613 (100.0%) 154 (40.1%) 14 (6.7%) 1,593 (79.0%)
The Americas 0 (0%) 0 (0%) 0 (0%) 83 (39.9%) 83 (4.1%)
Africa 0 (0%) 0 (0%) 230 (59.9%) 111 (53.4%) 341 (16.9%)
Prevalence of P. vivax
Low 301 (37.1%) 246 (40.1%) 223 (58.1%) 111 (53.4%) 881 (43.7%)
Moderate 61 (7.5%) 0 (0%) 28 (7.3%) 14 (6.7%) 103 (5.1%)
High 450 (55.4%) 367 (59.9%) 133 (34.6%) 83 (39.9%) 1,033 (51.2%)
Enrolment clinical variables
Parasitaemia, parasites per μL 4,458 (1,729–9,368) 2,240 (528–6,960) 4,282 (1,672–10,480) 3,400 (1,560–7,920) 3,599 (1,200–8,784)
Haemoglobin, g/dLa 11.7 (2.1) 12.4 (2.0) 12.1 (2.6) 13.4 (1.9) 12.2 (2.2)
Anaemic, haemoglobin < 10 g/dL 130/764 (17.0%) 55/612 (9.0%) 72/333 (21.6%) 4/184 (2.2%) 261/1,893 (13.8%)
Gametocytes present 524/570 (91.9%) 411/411 (100%) 218/281 (77.6%) 73/175 (41.7%) 1,226/1,437 (85.3%)
Fever, temperature > 37.5˚C 332/753 (44.1%) 260/556 (46.8%) 142/380 (37.4%) 58/124 (46.8%) 792/1,813 (43.7%)
Mg/kg dose calculated by tablet number 772/812 (95.1%) 112/613 (18.3%) 213/384 (55.5%) 184/208 (88.5%) 1,281/2,017 (63.5%)
Data are number (%), median (IQR), mean (SD), or n/N (%). Some percentages do not add up to 100, because of rounding.
aData not available for 124 of 2,017 patients: 48 in the DP alone group, 1 in the DP plus PQ group, 51 in the AL-alone group, and 24 in the AL plus PQ group.
Abbreviations: AL, artemether-lumefantrine; DP, dihydroartemisinin-piperaquine; IQR, interquartile range; PQ, primaquine; SD, standard deviation
https://doi.org/10.1371/journal.pmed.1002928.t001
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with a reduced rate of recurrence between days 7 and 42 (adjusted hazard ratio [AHR] for
every 5-mg/kg increase 0.63, 95% CI 0.48–0.84, p = 0.0013) (Table 2). Other factors associated
with P. vivax recurrence were short relapse periodicity (AHR 27.28, 95% CI 4.53–164.14,
p< 0.001) and lower baseline haemoglobin (AHR per g/dL 0.83, 95% CI 0.68–0.99, p =
0.0432). When the method of calculating the dose of drug was included in the model, it was
not an independent predictor of recurrence. In the sensitivity analysis, the coefficient of varia-
tion for piperaquine dose estimate was 6.08%, with AHRs ranging from 0.60 to 0.75 (S7
Table). The association between increased piperaquine dose and a reduced rate of recurrence
was also apparent when the follow period was extended to day 63 (AHR for every 5-mg/kg
increase 0.83, 95% CI 0.73–0.94, p = 0.0033).
To investigate the current WHO guidelines for DP dosing, piperaquine dosing was dichoto-
mised into a dose above and below the minimum WHO-recommended dose for P. falciparum
in the model. A piperaquine dose under the minimum WHO-recommended dose was associ-
ated with an increased rate of recurrence by day 42 (AHR 2.49, 95% CI 1.19–5.22, p = 0.0159).
By day 63, the association between piperaquine dose and the rate of recurrence was attenuated
(AHR 1.47, 95% CI 0.96–2.26, p = 0.0797), although it remained significant in children weigh-
ing <25 kg (AHR 2.33, 95% CI 1.18–4.62, p = 0.0149).
Schizontocidal treatment with AL alone
A total of 384 patients were treated with AL alone. The median total dose administered was
10.0 mg/kg (IQR 8.6–12.0; range 4.6–20.0) of artemether and 60.0 mg/kg (IQR 51.4–72.0;
range 27.7–120.0) of lumefantrine (S5 Fig and S6 Fig).
Following AL alone, 136 of 395 patients had a recurrence between days 7 and 42, with a
cumulative risk of recurrence of 21.0% (95% CI 16.9–25.8) at day 28 and 44.0% (95% CI 38.7–
49.8) at day 42. Of 14 patients with follow-up beyond day 42 and up to day 63, 11 (78.6%) had
Table 2. Risk factors for P. vivax recurrence between days 7 and 42 in patients treated with dihydroartemisinin-piperaquine alone.
Risk factor Total N (n)a Adjusted HR (95% CI) p-Value
Piperaquine dose, every 5-mg/kg increase 764 (41) 0.63 (0.48–0.84) 0.0013
Age, years
�15 432 (21) Reference -
<5 82 (14) 1.69 (0.68–4.23) 0.2615
5 to <15 250 (6) 0.70 (0.27–1.85) 0.4741
Gender
Male 441 (31) Reference -
Female 323 (10) 0.64 (0.31–1.32) 0.2231
Enrolment clinical variables
Parasitaemia, parasites per μL every 10-fold increase 764 (41) 1.19 (0.73–1.93) 0.4818
Haemoglobin, every 1-g/dL increase 764 (41) 0.83 (0.68–0.99) 0.0432
Relapse periodicity
Long 264 (2) Reference -
Short 500 (39) 27.28 (4.53–164.14) <0.001
Theta (variance of frailty parameter for clustering of study sites) = 0.41. The assumption of proportional hazards held for the model (p = 0.20 for global test). To examine
the robustness of the parameter estimates, a sensitivity analysis was carried out by removing one study site at a time, which showed that the overall coefficient of
variation for piperaquine dose estimates in the multivariable model was small (S7 Table).
aNumber of patients (number with recurrence by day 42).
Abbreviations: CI, confidence interval; HR, hazard ratio
https://doi.org/10.1371/journal.pmed.1002928.t002
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recurrent parasitaemia. Only one patient (0.3%) was administered less than the current dose of
lumefantrine recommended by WHO for P. falciparum (<29 mg/kg), and this patient did not
have a recurrent infection (S6 Fig). The median dose of lumefantrine was 65.5 mg/kg in
patients younger than 5 years and 53.3 mg/kg in those older than 5 years. After adjusting for
confounders and study-site clustering, there was no significant effect of lumefantrine dose on
rate of P. vivax recurrence (AHR per 5 mg/kg 1.07, 95% CI 0.99–1.16, p = 0.0869). Low base-
line haemoglobin was a risk factor for recurrence (Table 3).
Schizontocidal treatment AL versus DP
In the subgroup of patients not treated with PQ, the rate of P. vivax recurrence between days 7
and 42 was significantly greater following AL than DP after adjusting for confounders and
study-site clustering (AHR 12.63, 95% CI 6.40–24.92, p< 0.001) (Table 4). Because of violation
of the proportional hazards assumption, the analysis was undertaken separately, stratifying by
relapse periodicity. The high rate of recurrence after AL was apparent both in regions of short
relapse periodicity (AHR 6.56, 95% CI 4.04–10.65, p< 0.001) and long relapse periodicity
(AHR 81.40, 95% CI 19.58–338.45, p< 0.001) (Fig 2 and Table 4). In the sensitivity analysis,
there was minimal bias related to individual study sites (S8 Table). The difference between DP
and AL was also apparent in a subgroup analysis of the two studies comparing the treatments
directly (AHR 10.27, 95% CI 3.99–26.45, p< 0.001). The method of drug dose calculation was
not an independent predictor of recurrence when included in the overall model (AHR 0.57
[95% CI 0.19–1.70] for dosing based on the actual number of tablets administered compared
with that expected from study protocol; p = 0.3137).
Schizontocidal treatment plus PQ radical cure regimens
The median dose of PQ was 6.6 mg/kg (IQR 4.7–7.0; range 2.6–8.9) in patients treated with
DP and 3.3 mg/kg (IQR 3.1–3.8; range 0.3–9.1) in patients treated with AL. Of the patients
Table 3. Risk factors for P. vivax recurrence between days 7 and 42 in patients treated with artemether-lumefan-
trine alone.
Risk factor Total N (n)a Adjusted HR (95% CI) p-Value
Lumefantrine dose, every 5-mg/kg increase 333 (119) 1.07 (0.99–1.16) 0.0869
Age, years
�15 171 (37) Reference -
<5 59 (33) 1.41 (0.78–2.58) 0.2570
5 to <15 103 (49) 1.27 (0.71–2.27) 0.4110
Gender
Male 212 (69) Reference -
Female 121 (50) 0.85 (0.58–1.24) 0.3982
Enrolment clinical variables
Parasitaemia, parasites per μL every 10-fold increase 333 (119) 1.35 (0.96–1.89) 0.3982
Haemoglobin, every 1-g/dL increase 333 (119) 0.88 (0.80–0.96) 0.0862
Relapse periodicity
Long 216 (75) Reference -
Short 117 (44) 1.31 (0.79–2.15) 0.2917
Theta (variance of frailty parameter for clustering of study sites) = 0.01. The assumption of proportional hazards held
for the model (p = 0.33 for global test).
aNumber of patients (number with recurrence by day 42).
Abbreviations: CI, confidence interval; HR, hazard ratio
https://doi.org/10.1371/journal.pmed.1002928.t003
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Table 4. Multivariable model for rate of P. vivax recurrence between days 7 and 42 in patients receiving artemether-lumefantrine or dihydroartemisinin-pipera-
quine alone.
Risk factor All regions Long relapse periodicity Short relapse periodicity
Total N
(n)a
Adjusted HR
(95% CI)
p-Value Total N
(n)a
Adjusted HR
(95% CI)
p-Value Total N
(n)a
Adjusted HR
(95% CI)
p-Value
Treatment
Dihydroartemisinin-piperaquine 764 (41) Reference - 264 (2) Reference - 500 (39) Reference -
Artemether-lumefantrine 333 (119) 12.63 (6.40–
24.92)
<0.001 216 (75) 81.40 (19.58–
338.45)
<0.001 117 (44) 6.56 (4.04–10.65) <0.001
Age, per every 5-year increase 1,097
(160)
0.93 (0.87–1.00) 0.0562 480 (77) 0.88 (0.78–1.00) 0.0521 617 (83) 1.00 (0.91–1.09) 0.9153
Gender
Male 653 (100) Reference - 271 (45) Reference - 382 (55) Reference -
Female 444 (60) 0.74 (0.53–1.04) 0.0840 209 (32) 1.12 (0.70–1.79) 0.6269 235 (28) 0.47 (0.29–0.76) 0.0021
Parasitaemia, parasites per μL every
10-fold increase
1,097
(160)
1.44 (1.09–1.91) 0.0107 480 (77) 1.43 (0.86–2.38) 0.1700 617 (83) 1.37 (0.99–1.89) 0.0600
Baseline haemoglobin, every 1-g/dL
increase
1,097
(160)
0.87 (0.80–0.94) <0.001 480 (77) 0.84 (0.74–0.94) 0.0030 617 (83) 0.86 (0.78–0.96) 0.0053
Relapse periodicity
Long 480 (77) Reference - 480 (77) - - - - -
Short 617 (83) 2.95 (1.26–6.91) 0.0128 - - - 617 (83) - -
Theta (variance of frailty parameter for clustering of study sites for the model of all regions) = 0.35. The assumption of proportional hazards did not hold for the model
of all regions (p< 0.001 according to the global test, with p< 0.001 for relapse periodicity and p< 0.001 for treatment). There were interactions between treatment and
relapse periodicity and relapse periodicity and gender. For the model of patients from regions of long relapse periodicity alone, the assumption of proportional hazards
held (p = 0.19 according to the global test). For the model of patients from regions of short relapse periodicity alone, the AHR for treatment (artemether-lumefantrine
versus dihydroartemisinin-piperaquine) varied with time, with a higher AHR in the early follow-up to day 28 (AHR 18.48, 95% CI 7.32–46.69, p< 0.001) compared
with later follow-up after day 28 (AHR 4.11, 95% CI 2.29–7.38, p< 0.001, respectively), consistent with the difference in elimination half-lives between lumefantrine and
piperaquine. To examine the robustness of the parameter estimates, a sensitivity analysis was carried out by removing one study site at a time, which showed that the
overall coefficient of variation of parameter estimates in the multivariable models was minimal (S8 Table).
aNumber of patients (number with recurrence by day 42).
Abbreviations: AHR, adjusted HR; CI, confidence interval; HR, hazard ratio
https://doi.org/10.1371/journal.pmed.1002928.t004
Fig 2. Risk of recurrence (solid line, estimate; dashed lines, limits of 95% CI) adjusted for age, gender, relapse periodicity, baseline haemoglobin, and baseline
parasitaemia in patients receiving DP or AL alone in (A) short-periodicity regions (p< 0.001) and (B) long-periodicity regions (p< 0.001). Assumes zero effect
from study site; p-values derived from Cox model. AL, artemether-lumefantrine; CI, confidence interval; DP, dihydroartemisinin-piperaquine.
https://doi.org/10.1371/journal.pmed.1002928.g002
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treated with DP + PQ, 173 (28.2%) received a low-dose PQ regimen (<5 mg/kg), and 440
(71.8%) received a high-dose regimen (�5.0 mg/kg). The corresponding figures for AL + PQ
were 191 (91.8%) and 17 (8.2%).
There were three recurrences between days 7 and 42 in patients treated with DP + PQ, with
a cumulative risk of recurrence of 0.2% (95% CI 0.0–1.2) at day 28 and 1.0% (95% CI 0.3–3.2)
at day 42. Of the 55 patients with follow-up beyond day 42, a further two patients had a recur-
rence between days 42 and 63: cumulative risk 5.2% (95% CI 1.7–15.5) at day 63. There were
nine recurrences between days 7 and 42 in patients treated with AL + PQ, with a cumulative
risk of recurrence of 2.7% (95% CI 1.1–6.3) at day 28 and 5.3% (95% CI 2.8–10.0) at day 42.
Two of five patients followed beyond day 42 had a recurrence between days 42 and 63.
In a multivariable model of patients treated with DP, recurrence by day 42 was not reduced
significantly by coadministration of PQ (AHR = 0.23, 95% CI 0.04–1.28, p = 0.0933). However,
in patients treated with AL, coadministration of PQ reduced the rate of recurrence (AHR =
0.20, 95% CI 0.10–0.41, p< 0.001) (Fig 3 and S9 Table). When PQ dose was included in the
model of patients treated with DP, neither low-dose PQ (AHR = 0.28, 95% CI 0.04–1.99,
p = 0.2031) nor high-dose PQ (AHR = 0.15, 95% CI 0.01–1.96, p = 0.1494) was associated with
reduced rate of recurrence. In patients treated with AL, low-dose PQ reduced the rate of recur-
rence (AHR = 0.21, 95% CI 0.10–0.41, p< 0.001; of note, only 17 patients received high-dose
PQ) (S10 Table). In a subset analysis including five studies following patients to day 63 or
more, coadministration of any dose of PQ with DP reduced the rate of recurrence
(AHR = 0.06, 95% CI 0.01–0.63, p = 0.0196) (S11 Table). In a sensitivity analysis, reductions in
rate of recurrence with PQ were unlikely to be attributable to bias from individual study sites
(S12 Table). Because of the low number of recurrences, a multivariable analysis comparing the
risk of recurrence with DP + PQ and AL + PQ could not be done.
Time to P. vivax recurrence and haematological recovery
In total, of the 160 patients with recurrence between day 7 and day 63 treated with DP with or
without PQ, 12 had available data on the haemoglobin at the day of recurrence, 6 (50.0%) of
which were symptomatic recurrences. The corresponding numbers for patients treated with
Fig 3. Risk of recurrence (solid line, estimate; dashed lines, limits of 95% CI) adjusted for age, mg/kg piperaquine or lumefantrine dose, gender, relapse
periodicity, baseline haemoglobin, and baseline parasitaemia comparing treatment with and without PQ in patients receiving (A) dihydroartemisinin-
piperaquine (p = 0.0933) or (B) artemether-lumefantrine (p< 0.001). Assumes zero effect from study site; p-values derived from Cox model. CI, confidence
interval; PQ, primaquine.
https://doi.org/10.1371/journal.pmed.1002928.g003
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AL were 109 patients with available data out of 158 patients with recurrence between day 7
and day 63, with 70 (64.2%) of these patients having symptomatic recurrence.
Because of the low number of recurrences after DP +/− PQ, a multivariable analysis assessing
the effect of day of recurrence on haemoglobin could not be undertaken. For patients treated
with AL +/− PQ, there was a nonsignificant increase in haemoglobin of 0.07 g/dL (95% CI
−0.06 to 0.20), p = 0.3130 for every 5 days that recurrence was delayed. When the analysis was
restricted to symptomatic recurrences, the mean haemoglobin at recurrence increased 0.13 g/
dL (95% CI 0.01–0.26) for every 5 days that recurrence was delayed (p = 0.0407) (S13 Table).
Discussion
In response to emerging resistance of P. vivax to chloroquine and the pragmatic advantages of
a universal treatment policy, some countries are recommending ACTs for all species of
malaria. Nevertheless, the optimal ACT for P. vivax remains unclear [10,11]. The pattern of
relapse following antimalarial treatment is determined by the elimination kinetics of the schi-
zontocidal treatment. In this meta-analysis of data from more than 2,000 individual patients,
the risk of early vivax recurrence up to day 42 was 12.6-fold higher following AL than DP. This
difference was apparent despite 37.3% of patients receiving DP doses below those recom-
mended for P. falciparum, with these patients having a 2.5-fold increased rate of recurrence
compared with those receiving a higher dose. However, by day 63, the risk of recurrence was
greater than 39.9% following treatment with either ACT. This suggests that the prolonged
half-life of piperaquine in DP may have only been delaying the time to the first patent relapse,
as reported previously in comparisons of rapidly and slowly eliminated antimalarial drugs
(quinine and mepacrine, artesunate and chloroquine) [2,44]. Coadministration of PQ was
associated with the greatest reduction in the risk of P. vivax recurrence, with an 80% reduction
following AL at day 42 and a 92% reduction following DP at day 63.
ACT is the recommended treatment for P. falciparum asexual stages [19]. Lumefantrine,
piperaquine, and mefloquine all have high antimalarial activity against P. vivax [26,45–48];
however, they differ markedly in their pharmacokinetic profiles. ACTs achieve their antima-
larial effect through an initial rapid reduction in parasite biomass attributable to the short-act-
ing but potent artemisinin derivative, with the subsequent removal of the remaining parasites
by the intrinsically less active but more slowly eliminated lumefantrine (terminal elimination
half-life of approximately 4 days) or piperaquine (terminal elimination half-life of 28–35 days)
[49–51]. After eradication of the asexual stages of the parasite from the peripheral blood,
patients who remain in an endemic area are at risk of reinfection or, following P. vivax, from
relapses from the liver-stage hypnozoites. Slowly eliminated ACT partner drugs exert a longer
post-treatment prophylactic effect than more rapidly eliminated partner drugs, and this is
reflected in both the rates and timing of reinfection and relapse [10]. The greater the risk of P.
vivax relapse or reinfection with either species, the more apparent is this prophylactic effect. In
our analysis, 70% of patients were followed for 42 days or less, and only 5% of patients were
followed beyond 63 days, preventing a comprehensive assessment of the comparative efficacies
of DP and AL on later recurrences. Hence, we were unable to determine whether the lower
rate of recurrence following DP was the result of a reduction in the total number of relapses or
merely due to a delay in the first relapse with a similar total number of relapses occurring after
blood drug concentrations fall below the minimum inhibitory concentration.
Following a large meta-analysis of patients with P. falciparum and confirmatory pharmaco-
kinetic–pharmacodynamic analysis [20,21], WHO recommended that the total dose of pipera-
quine in patients with P. falciparum be increased from a lower cutoff of�48 mg/kg in all ages
to�60 mg/kg in children weighing<25 kg [19]. As yet, there are no guidelines on ACT dosing
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specifically for P. vivax, and thus, recommended doses are extrapolated from those derived for
P. falciparum [19]. To our knowledge, our analysis provides the first large-scale dosing assess-
ment of AL and DP in patients with P. vivax. Only one patient treated with AL alone was given
a dose less than that recommended for P. falciparum, and there was no evidence that dosing
should be different in P. vivax. In contrast, almost 40% of patients treated with DP were under-
dosed with piperaquine compared with the updated dosing guidelines for P. falciparum. At
day 42, these patients were at 2.5-fold higher risk of recurrence compared with patients pre-
scribed the dose recommended for P. falciparum. The effect of piperaquine dose was still
apparent at day 63, although this only reached statistical significance in patients < 25 kg, who
had a 2.3-fold higher risk of recurrence when underdosed. These results highlight the need for
patient-centred dosing to ensure individual patients receive an appropriate dose based on
body weight.
Although PQ has been used in conjunction with chloroquine for over 60 years, its combina-
tion with ACTs has been used only recently. Lumefantrine is an inhibitor of cytochrome P450
(CYP)2D6 in vitro [52,53], an enzyme considered responsible for biotransformation of PQ to
its active metabolites, and this has led to concerns that coadministration will reduce the effi-
cacy of PQ [54]. PQ pharmacokinetics are related to CYP2D6 activity, regardless of whether
patients are treated with AL plus PQ, suggesting that any inhibition of CYP2D6 by lumefan-
trine is incomplete [55]. The current study is reassuring, demonstrating that coadministration
of PQ and AL results in an 80% reduction in the rate of recurrence by day 42. Although reduc-
tion in P. vivax following coadministration of DP and PQ did not reach statistical significance
at day 42, this was likely because of the relatively few recurrences at this time following DP
alone, because by day 63, the risk of recurrence was reduced by over 90%.
Our study has a number of limitations. Only 68% of potentially eligible patient records
were included in the analysis. There were some minor differences in age and sex between
included and targeted patient records; however, included studies were more recent and
included a more balanced sex distribution. Data for mg/kg dose were based on the study pro-
tocol rather than the number of tablets received in about one-third of patients. However, the
method of dose calculation was not a significant predictor of recurrence, and over 95% of
patients treated with DP alone had complete dosing data available, suggesting this is unlikely
to have impacted upon our analysis.
Analysis was restricted to patients with follow-up to day 42 or less for AL, but in 62% of
patients treated with DP, follow-up was available up to day 63. Comparison of recurrences
between two drugs’ regimens with markedly different pharmacokinetic profiles exerting differ-
ent post-treatment prophylaxis within this time period therefore needs to be interpreted with
caution. Furthermore, admixture of new infections with relapses will be different with the two
drugs, and recrudescence, relapse, and reinfection were not separated in these studies. In a
post hoc analysis, a delay in the time to recurrence in patients treated with AL resulted in a
higher mean haemoglobin at the time of recurrence. Hence, even if DP is delaying rather than
preventing relapses, it likely offers a greater time for haematological recovery between the ini-
tial infection and the next recurrence and, thus, potential clinical benefits. Additional studies
are warranted to quantify the longer-term benefits of prolonged parasite prophylaxis on the
number of total relapses and cumulative risk of anaemia. Importantly, only two of the studies
included in our analysis compared AL and DP directly, and none of the studies compared AL
+ PQ and DP + PQ; thus, treatment was not randomised, potentially confounding the inter-
pretation of the comparative efficacies and the effect of relapse periodicity. However, reassur-
ingly, when the analysis was restricted to these two studies, the results remained consistent.
In summary, these findings suggest that early recurrence of P. vivax parasitaemia can be
reduced significantly in patients treated with DP compared with AL. Despite the relatively low
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risk of early recurrence with DP, over one-third of patients received a dose less than that rec-
ommended in the current P. falciparum treatment guidelines, and this was associated with an
increased risk of P. vivax recurrence. Although by day 63 there was a high risk of P. vivax
recurrence after both AL and DP, coadministration with PQ reduced this substantially. Our
findings support recommendations that ACTs should be combined with PQ and suggest that
in patients in which PQ is contraindicated, DP may provide early clinical benefits over AL
alone.
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